1. Platelet Glycoprotein IIb/IIIa Inhibitors in Percutaneous Coronary Intervention

   • Ian C. Gilchrist

   Review Article 13 September 2012 Pages: 703 - 720

   

2. Pharmacokinetic-Pharmacodynamic Relationships of Immunoglobulin Therapy for Envenomation

   • José María Gutiérrez
   • Guillermo León
   • Bruno Lomonte

   Review Article 13 September 2012 Pages: 721 - 741

   

3. Influence of Severe Renal Impairment on the Pharmacokinetics and Pharmacodynamics of Oral Ximelagatran and Subcutaneous Melagatran

   • Ulf G. Eriksson
   • Susanne Johansson
   • Ola Samuelsson

   Original Research Article 13 September 2012 Pages: 743 - 753

   

4. No Influence of Mild-To-Moderate Hepatic Impairment on the Pharmacokinetics and Pharmacodynamics of Ximelagatran, an Oral Direct Thrombin Inhibitor

   • Karin Wåhlander
   • Maria Eriksson-Lepkowska
   • Ulf G. Eriksson

   Original Research Article 13 September 2012 Pages: 755 - 764

   

5. Ximelagatran, an Oral Direct Thrombin Inhibitor, Has a Low Potential for Cytochrome P450-Mediated Drug-Drug Interactions

   • Eva Bredberg
   • Tommy B. Andersson
   • Ulf G. Eriksson

   Original Research Article 13 September 2012 Pages: 765 - 777